Brazil Pharmaceuticals and Healthcare Report Q2 2016

109 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Brazil will continue to be the most important market for multinational pharmaceutical
companies in Latin America, despite growing financial tensions, increasing pricing pressure and generic
competition. Headline Expenditure Projections
Pharmaceuticals: BRL65.8bn (USD19.8bn) in 2015 to BRL69.8bn (USD18.4bn) in 2016; +6.1% in local
currency terms and -7.0% in US dollar terms. Forecast in has stayed the same as in Q116.
Healthcare: BRL509.9bn (USD216.7bn) in 2015 to BRL601.1bn (USD158.2bn) in 2016; +8.3% in local
currency terms and -5.0% in US dollar terms. Forecast in local currency has been revised downward from
Q116.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Brazil 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020) 22
Generic Drug Market Forecast 23
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020) 25
OTC Medicine Market Forecast 26
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2012-2020) 27
Pharmaceutical Trade Forecast 28
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2014-2020) 30
Industry Risk/Reward Index 31
Americas Risk/Reward Index 31
Brazil Risk/Reward Index 37
Rewards 37
Risks 37
Regulatory Review 39
Intellectual Property Issues 40
Pricing Regime 43
Reimbursement Regime 44
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Brazil 2010-2015) 49
Table: Healthcare Personnel (Brazil 2010-2015) 49
Table: Healthcare Activity (Brazil 2010-2015) 50
Research & Development 50
Biotechnology 52
Clinical Trials 53
Epidemiology 54
Competitive Landscape 57
Research-Based Industry 57
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013 57
Table: Multinational Pharmaceutical Company Activity 58
Generic Drugmakers 58
Pharmaceutical Distribution 61
Pharmaceutical Retail Sector 63
Company Profile 65
Aché/Biosintética 65
Cristália 69
EMS Sigma 72
Eurofarma 75
GlaxoSmithKline 77
Table: GlaxoSMITHKLINE'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil 79
Medley 81
Merck & Co 83
Novartis 86
Pfizer 89
Roche 92
Sanofi 95
Demographic Forecast 98
Table: Population Headline Indicators (Brazil 1990-2025) 99
Table: Key Population Ratios (Brazil 1990-2025) 99
Table: Urban/Rural Population & Life Expectancy (Brazil 1990-2025) 100
Table: Population By Age Group (Brazil 1990-2025) 100
Table: Population By Age Group % (Brazil 1990-2025) 101
Glossary 103
Methodology 105
Pharmaceutical Expenditure Forecast Model 105
Healthcare Expenditure Forecast Model 105
Notes On Methodology 106
Risk/Reward Index Methodology 107
Index Overview 108
Table: Pharmaceutical Risk/Reward Index Indicators 108
Indicator Weightings 109

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Brazil 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Brazil 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Brazil 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Brazil 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Brazil 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Brazil 2014-2020)
Table: Healthcare Resources (Brazil 2010-2015)
Table: Healthcare Personnel (Brazil 2010-2015)
Table: Healthcare Activity (Brazil 2010-2015)
Table: Top 10 Pharmaceutical Companies In Brazil By Sales In 2013
Table: Multinational Pharmaceutical Company Activity
Table: GlaxoSMITHKLINE'S Strong Collaborative Efforts In Public-Private Partnerships (Ppps) In Brazil
Table: Population Headline Indicators (Brazil 1990-2025)
Table: Key Population Ratios (Brazil 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Brazil 1990-2025)
Table: Population By Age Group (Brazil 1990-2025)
Table: Population By Age Group % (Brazil 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Brazil Pharmaceuticals and Healthcare Report Q3 2016BMI View: The current state of political uncertainty will not shake Brazil's leading position as Latin America's largest pharmaceutical and healthcare market. The Brazilian government has been committed to improving the population's access to healthcare for decades. Having said this, Brazil's private healthcare market will experience contraction in real terms in 2016 due to the deteriorating political and economic outlook. Headline Expenditure Projections Pharmaceuticals: BRL66.8bn […]
  • Serbia Pharmaceuticals and Healthcare Report Q2 2016BMI View: The Serbian pharmaceutical and healthcare market remains one of the least attractive within the CEE region for foreign drugmakers. Government cost containment, implemented through severe drug price cuts by the RFZO, will dampen growth. Furthermore, an increasing reliance on private health spending will impact pharmaceutical sales as the worsening macroeconomic outlook will reduce consumer spending power. Headline Expenditure Projections Pharmaceuticals: RSD91.42bn […]
  • Argentina Pharmaceuticals and Healthcare Report Q2 2016BMI View: Over the next five years, Argentina's pharmaceutical and healthcare sector growth trends are expected to substantially benefit from the improving business environment, including the liberalisation of the country's external accounts. Moreover, Argentina's geographical proximity, strong drug production ability and a skilled workforce will provide excellent investment opportunities for foreign drugmakers to expand their presence in Latin America, including through local market […]
  • Brazil Pharmaceuticals and Healthcare Report Q3 2014BMI View: The Brazilian pharmaceutical market will continue to be the most attractive to multinational pharmaceutical companies in Latin America. Strong government support, an improving regulatory regime and significant private healthcare growth mean that the market presents significant revenue-generating opportunities for drugmakers and healthcare service providers. However, multinationals will continue to face increasing drug pricing pressure and domestic competition. Headline […]
  • Brazil Pharmaceuticals and Healthcare Report Q2 2015BMI View: Continued regulatory improvements, growing pharmaceutical and healthcare markets, and increased favour for foreign investment will allow Brazil to maintain its position as the regional outperformer in Latin America. However, low affordability and increasing generic drug competition will hamper opportunities for innovative drugmakers as the country continues to develop its economy. Headline Expenditure Projections Pharmaceuticals: BRL62.0bn (USD26.3bn) in 2014 to BRL65.3bn […]